Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery.
Consensus
Dose prescription
ICRU report 91
Radiation oncology
Stereotactic body radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
received:
29
05
2024
accepted:
02
06
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
12
7
2024
Statut:
aheadofprint
Résumé
To develop expert consensus statements on multiparametric dose prescriptions for stereotactic body radiotherapy (SBRT) aligning with ICRU report 91. These statements serve as a foundational step towards harmonizing current SBRT practices and refining dose prescription and documentation requirements for clinical trial designs. Based on the results of a literature review by the working group, a two-tier Delphi consensus process was conducted among 24 physicians and physics experts from three European countries. The degree of consensus was predefined for overarching (OA) and organ-specific (OS) statements (≥ 80%, 60-79%, < 60% for high, intermediate, and poor consensus, respectively). Post-first round statements were refined in a live discussion for the second round of the Delphi process. Experts consented on a total of 14 OA and 17 OS statements regarding SBRT of primary and secondary lung, liver, pancreatic, adrenal, and kidney tumors regarding dose prescription, target coverage, and organ at risk dose limitations. Degree of consent was ≥ 80% in 79% and 41% of OA and OS statements, respectively, with higher consensus for lung compared to the upper abdomen. In round 2, the degree of consent was ≥ 80 to 100% for OA and 88% in OS statements. No consensus was reached for dose escalation to liver metastases after chemotherapy (47%) or single-fraction SBRT for kidney primaries (13%). In round 2, no statement had 60-79% consensus. In 29 of 31 statements a high consensus was achieved after a two-tier Delphi process and one statement (kidney) was clearly refused. The Delphi process was able to achieve a high degree of consensus for SBRT dose prescription. In summary, clear recommendations for both OA and OS could be defined. This contributes significantly to harmonization of SBRT practice and facilitates dose prescription and reporting in clinical trials investigating SBRT.
Identifiants
pubmed: 38997440
doi: 10.1007/s00066-024-02254-2
pii: 10.1007/s00066-024-02254-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Seuntjens L, Lartigau EF, Cora S (2017) Bethesda, MD: International Commission on Radiation Units & Measurements. ICRU Report 91, Prescribing, Recording, and Reporting of Stereotactic Treatments with Small Photon Beams. In, vol 91
Wilke L, Andratschke N, Blanck O, Brunner TB, Combs SE, Grosu AL, Moustakis C, Schmitt D, Baus WW, Guckenberger M (2019) ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 195(3):193–198
Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, Gauer T, Grosu AL, Schmitt D, Tanadini-Lang S et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 196(5):417–420
Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B, Manser P, Werner R, Wilhelm ML et al (2020) Technological quality requirements for stereotactic radiotherapy: Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 196(5):421–443
Brunner T (2022) A story of hypofractionation and the “Table on the Wall”]. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft. Et Al 198(8):759–760
Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN, Oechsner M, Ganswindt U, Heinz C et al (2017) Planning benchmark study for SBRT of early stage NSCLC: Results of the DEGRO Working Group Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 193(10):780–790
Wilke L, Moustakis C, Blanck O, Albers D, Albrecht C, Avcu Y, Boucenna R, Buchauer K, Etzelstorfer T, Henkenberens C et al (2021) Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 197(9):836–846
Moustakis C, Blanck O, Chan MKH, Boda-Heggemann J, Andratschke N, Duma MN, Albers D, Baumer C, Fehr R, Korber SA et al (2022) Planning Benchmark Study for Stereotactic Body Radiation Therapy of Liver Metastases: Results of the DEGRO/DGMP Working Group on Stereotactic Radiation Therapy and Radiosurgery. Int J Radiat Oncol Biol Phys 113(1):214–227
pubmed: 35074434
doi: 10.1016/j.ijrobp.2022.01.008
Moustakis C, Blanck O, Grohmann M, Malek AH, Albers D, Bathen B, Barbiero S, Bartels D, Broggi S, Borzi GR et al (2024) Planning benchmark study for stereotactic body radiation therapy of pancreas carcinomas with simultaneously integrated boost and protection: results of the DEGRO/DGMP Working Group on stereotactic radiation therapy and radiosurgery. Int J Radiat Oncol Biol Phys
Ashford N, Simpson V, Armstead J (1966) I don’t need no doctor. In: A Man and His Soul. Charles R (ed), Ashford
Guckenberger M, Klement RJ, Allgauer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U et al (2016) Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol 118(3):485–491
pubmed: 26385265
doi: 10.1016/j.radonc.2015.09.008
Klement RJ, Sonke JJ, Allgauer M, Andratschke N, Appold S, Belderbos J, Belka C, Blanck O, Dieckmann K, Eich HT et al (2020) Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. Int J Radiat Oncol Biol Phys 107(3):579–586
pubmed: 32188579
doi: 10.1016/j.ijrobp.2020.03.005
Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, Sauer O, Deutschen Gesellschaft fur R (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 190(1):26–33
Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 190(10):872–881
Panje C, Andratschke N, Brunner TB, Niyazi M, Guckenberger M (2016) Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer: Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 192(12):875–885
Patton C, Bradfield L (2019) ASTRO clinical practice. Guideline methodology guide. In
Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK, Lyman GH, Basch E, Americal Society of Clinical Oncology Clinical Practice G (2012) American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 30(25):3136–3140
pubmed: 22778311
doi: 10.1200/JCO.2012.42.0489
Kroese TE, van Laarhoven HWM, Schoppman SF, Deseyne P, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR et al (2023) Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer 185:28–39
pubmed: 36947929
doi: 10.1016/j.ejca.2023.02.015
Timmerman R (2022) A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys 112(1):4–21. https://doi.org/10.1016/j.ijrobp.2021.09.027
doi: 10.1016/j.ijrobp.2021.09.027
pubmed: 34919882
Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, Conibear J, Dunne EM, Eaton DJ, Franks KN et al (2022) UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clin Oncol (R Coll Radiol) 34(5):288–300. https://doi.org/10.1016/j.clon.2022.02.010
doi: 10.1016/j.clon.2022.02.010
pubmed: 35272913
Toesca DA, Osmundson EC, Eyben RV, Shaffer JL, Lu P, Koong AC, Chang DT (2017) Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. Radiother Oncol 122(1):130–136. https://doi.org/10.1016/j.radonc.2016.10.024
doi: 10.1016/j.radonc.2016.10.024
pubmed: 27865544
Klement RJ, Guckenberger M, Alheid H, Allgauer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S et al (2017) Stereotactic body radiotherapy for oligo-metastatic liver disease—Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 123(2):227–233. https://doi.org/10.1016/j.radonc.2017.01.013
doi: 10.1016/j.radonc.2017.01.013
pubmed: 28274491
Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, Ringash J, Dawson LA (2014) Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 111(3):412–417. https://doi.org/10.1016/j.radonc.2014.05.002
doi: 10.1016/j.radonc.2014.05.002
pubmed: 24906626
Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M et al (2022) 5‑year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23(12):1508–1516. https://doi.org/10.1016/S1470-2045(22)00656-8
doi: 10.1016/S1470-2045
Mizowaki T (2022) SABR for primary renal cell carcinoma: single-fraction or multiple-fraction? Lancet Oncol 23(12):1476–1477. https://doi.org/10.1016/S1470-2045(22)00697-0
doi: 10.1016/S1470-2045
Buergy D, Wurschmidt F, Gkika E, Horner-Rieber J, Knippen S, Gerum S, Balermpas P, Henkenberens C, Voglhuber T, Kornhuber C et al (2022) Stereotactic body radiotherapy of adrenal metastases‑A dose-finding study. Int J Cancer 151(3):412–421
pubmed: 35383919
doi: 10.1002/ijc.34017
Brauckhoff M, Gimm O, Thanh PN, Bar A, Ukkat J, Brauckhoff K, Bonsch T, Dralle H (2003) Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery 134(6):1020–1027 (discussion 1027–1028)
pubmed: 14668736
doi: 10.1016/j.surg.2003.08.005
Guckenberger M, Klement RJ, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M et al (2013) Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol 109(1):13–20
pubmed: 24183066
doi: 10.1016/j.radonc.2013.09.005
Brunner TB, Nestle U, Grosu AL, Partridge M (2015) SBRT in pancreatic cancer: what is the therapeutic window? Radiother Oncol 114(1):109–116
pubmed: 25466369
doi: 10.1016/j.radonc.2014.10.015
Worm ES, Hoyer M, Fledelius W, Hansen AT, Poulsen PR (2013) Variations in magnitude and directionality of respiratory target motion throughout full treatment courses of stereotactic body radiotherapy for tumors in the liver. Acta Oncol 52(7):1437–1444
pubmed: 23879645
doi: 10.3109/0284186X.2013.813638
van der Merwe D, Van Dyk J, Healy B, Zubizarreta E, Izewska J, Mijnheer B, Meghzifene A (2017) Accuracy requirements and uncertainties in radiotherapy: a report of the International Atomic Energy Agency. Acta Oncol 56(1):1–6
pubmed: 27846757
doi: 10.1080/0284186X.2016.1246801
Chen G, Dong B, Shan G, Zhang X, Tang H, Li Y, Wang Z, Xu W, Xu G, Yan G et al (2019) Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI. Bmc Cancer 19(1):583
pubmed: 31200687
pmcid: 6570957
doi: 10.1186/s12885-019-5767-1
Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR et al (2006) The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med Phys 33(10):3874–3900
pubmed: 17089851
doi: 10.1118/1.2349696
Bouilhol G, Ayadi M, Rit S, Thengumpallil S, Schaerer J, Vandemeulebroucke J, Claude L, Sarrut D (2013) Is abdominal compression useful in lung stereotactic body radiation therapy? A 4DCT and dosimetric lobe-dependent study. Phys Med 29(4):333–340
pubmed: 22617761
doi: 10.1016/j.ejmp.2012.04.006
Mancosu P, Castiglioni S, Reggiori G, Catalano M, Alongi F, Pellegrini C, Arcangeli S, Tozzi A, Lobefalo F, Fogliata A et al (2012) Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. Radiat Oncol 7:16
pubmed: 22296849
pmcid: 3292972
doi: 10.1186/1748-717X-7-16
Zhang S, Zhan W, Zeng N, Yang J, Xiong M, Liao W, Chen N, Xiao J (2023) Dosimetric comparison in sparing normal tissue dosage by using auto-SBRT planning in oligo liver tumors. Front Oncol 13:1273042
pubmed: 38023203
pmcid: 10665725
doi: 10.3389/fonc.2023.1273042
Papiez L, Timmerman R, DesRosiers C, Randall M (2003) Extracranial stereotactic radioablation: physical principles. Acta Oncol 42(8):882–894
pubmed: 14968949
doi: 10.1080/02841860310013490
Varasteh M, Ali A, Esteve S, Jeevanandam P, Gopfert F, Irvine DM, Hounsell AR, McGarry CK (2023) Patient specific evaluation of breathing motion induced interplay effects. Phys Med 105:102501
pubmed: 36529007
doi: 10.1016/j.ejmp.2022.11.005
Court LE, Wagar M, Ionascu D, Berbeco R, Chin L (2008) Management of the interplay effect when using dynamic MLC sequences to treat moving targets. Med Phys 35(5):1926–1931
pubmed: 18561668
doi: 10.1118/1.2896083
Hubley E, Pierce G (2017) The influence of plan modulation on the interplay effect in VMAT liver SBRT treatments. Phys Med 40:115–121
pubmed: 28784572
doi: 10.1016/j.ejmp.2017.07.025
Brunner TB, Nestle U, Adebahr S, Gkika E, Wiehle R, Baltas D, Grosu AL (2016) Simultaneous integrated protection: A new concept for high-precision radiation therapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 192(12):886–894
Simoni N, Micera R, Paiella S, Guariglia S, Zivelonghi E, Malleo G, Rossi G, Addari L, Giuliani T, Pollini T et al (2021) Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Clin Oncol (R Coll Radiol) 33(1):e31–e38
Maranzano E, Draghini L, Anselmo P, Casale M, Arcidiacono F, Chirico L, Italiani M, Trippa F (2016) Lung reirradiation with stereotactic body radiotherapy. J Radiosurg SBRT 4(1):61–68
pubmed: 29296427
pmcid: 5658839
John C, Dal Bello R, Andratschke N, Guckenberger M, Boda-Heggemann J, Gkika E, Mantel F, Specht HM, Stromberger C, Zehentmayr F et al (2021) In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). Sci Rep 11(1):4590
pubmed: 33633130
pmcid: 7907095
doi: 10.1038/s41598-021-83210-3
Kinj R, Casutt A, Bennassi A, Bouchaab H, Vallet V, Lovis A, Ozsahin M (2021) Stereotactic lung reirradiation for local relapse: A case series. Clin Transl. Radiat Oncol 28:85–87
Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, Fritsch R, Brass V, Maruschke L, Neeff HP et al (2019) Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 195(3):246–253
Das IJ, Francescon P, Moran JM, Ahnesjo A, Aspradakis MM, Cheng CW, Ding GX, Fenwick JD, Saiful Huq M, Oldham M et al (2021) Report of AAPM Task Group 155: Megavoltage photon beam dosimetry in small fields and non-equilibrium conditions. Med Phys 48(10):e886–e921
pubmed: 34101836
doi: 10.1002/mp.15030
Matsuoka T, Araki F, Ohno T, Sakata J, Tominaga H (2019) Dependence of volume dose indices on dose calculation algorithms for VMAT-SBRT plans for peripheral lung tumor. Med Dosim 44(3):284–290
pubmed: 30455092
doi: 10.1016/j.meddos.2018.10.004
Inoue K, Matsukawa H, Kasai Y, Edamitsu K, Matsumoto K, Suetsugu Y, Hirose TA, Fukunaga JI, Shioyama Y, Sasaki T (2023) Difference in target dose distributions between Acuros XB and collapsed cone convolution/superposition and the impact of the tumor locations in clinical cases of stereotactic ablative body radiotherapy for lung cancer. J Cancer Res Ther 19(5):1261–1266
pubmed: 37787293
doi: 10.4103/jcrt.jcrt_1740_21
Kry SF, Alvarez P, Molineu A, Amador C, Galvin J, Followill DS (2013) Algorithms used in heterogeneous dose calculations show systematic differences as measured with the Radiological Physics Center’s anthropomorphic thorax phantom used for RTOG credentialing. Int J Radiat Oncol Biol Phys 85(1):e95–100
pubmed: 23237006
pmcid: 3522855
doi: 10.1016/j.ijrobp.2012.08.039
Dunn L, Lehmann J, Lye J, Kenny J, Kron T, Alves A, Cole A, Zifodya J, Williams I (2015) National dosimetric audit network finds discrepancies in AAA lung inhomogeneity corrections. Phys Med 31(5):435–441
pubmed: 25921329
doi: 10.1016/j.ejmp.2015.04.002
Lambrecht ML, Eaton DJ, Sonke JJ, Nestle U, Peulen H, Weber DC, Verheij M, Hurkmans CW (2019) Results of a multicentre dosimetry audit using a respiratory phantom within the EORTC LungTech trial. Radiother Oncol 138:106–113
pubmed: 31252291
doi: 10.1016/j.radonc.2019.06.008
Josipovic M, Persson GF, Rydhog JS, Smulders B, Thomsen JB, Aznar MC (2018) Advanced dose calculation algorithms in lung cancer radiotherapy: Implications for SBRT and locally advanced disease in deep inspiration breath hold. Phys Med 56:50–57
pubmed: 30527089
doi: 10.1016/j.ejmp.2018.11.013
Kry SF, Lye J, Clark CH, Andratschke N, Dimitriadis A, Followill D, Howell R, Hussein M, Ishikawa M, Kito S et al (2021) Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. Radiother Oncol 159:106–111
pubmed: 33741471
doi: 10.1016/j.radonc.2021.03.006
Snyder Karen C, Liu M, Zhao B, Huang Y, Ning W, Chetty IJ, Siddiqui MS (2017) Investigating the dosimetric effects of grid size on dose calculation accuracy using volumetric modulated arc therapy in spine stereotactic radiosurgery. J Radiosurg SBRT 4(4):303–313
pubmed: 29296454
pmcid: 5658825
Kroon PS, Hol S, Essers M (2013) Dosimetric accuracy and clinical quality of Acuros XB and AAA dose calculation algorithm for stereotactic and conventional lung volumetric modulated arc therapy plans. Radiat Oncol 8:149
pubmed: 23800024
pmcid: 3723919
doi: 10.1186/1748-717X-8-149
Hernandez S, Sjogreen C, Gay SS, Nguyen C, Netherton T, Olanrewaju A, Zhang LJ, Rhee DJ, Mendez JD, Court LE et al (2021) Development and dosimetric assessment of an automatic dental artifact classification tool to guide artifact management techniques in a fully automated treatment planning workflow. Comput Med Imaging Graph 90:101907
pubmed: 33845433
pmcid: 8180493
doi: 10.1016/j.compmedimag.2021.101907
Greco LTG, Vu K (2024) Dosimetric significance of manual density overrides in oropharyngeal cancer. Med Dosim
de Jong EEC, Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Milder M, Moller DS, Nyeng TB, Tanadini-Lang S, Lartigau E et al (2020) Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. Radiother Oncol 142:217–223
pubmed: 31767472
doi: 10.1016/j.radonc.2019.11.001
Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, Hashemi S, Nossent E, Spoelstra F, de Langen AJ et al (2016) Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non-Small Cell Lung Cancer. J Thorac Oncol 11(7):1081–1089
pubmed: 27013408
doi: 10.1016/j.jtho.2016.03.008
Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersall P, Persson GF, Josipovic M, Khalil AA, Moeller DS et al (2021) The HILUS-Trial‑a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol 16(7):1200–1210
pubmed: 33823286
doi: 10.1016/j.jtho.2021.03.019
Chang JH, Poon I, Erler D, Zhang L, Cheung P (2018) The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors. Radiother Oncol 129(2):277–283
pubmed: 30049454
doi: 10.1016/j.radonc.2018.07.001
Giuliani ME, Filion EJ, Faria S, Kundapur V, Vu TTT, Lok BH, Raman S, Bahig H, Laba JM, Lang P et al (2023) Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET). In ASTRO Annual Meeting: January 01, 2024 2023, San Diego, USA, Elsevier, E2
Levy A, Adebahr S, Hurkmans C, Ahmed M, Ahmad S, Guckenberger M, Geets X, Lievens Y, Lambrecht M, Pourel N, Lewitzki V, Konopa K, Franks K, Dziadziuszko R, McDonald F, Fortpied C, Clementel E, Fournier B, Rizzo S, Fink C, Riesterer O, Peulen H, Andratschke N, McWilliam A, Gkika E, Schimek-Jasch T, Grosu AL, Le Pechoux C, Faivre-Finn C, Nestle U (2024) Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2024.05.366
doi: 10.1016/j.jtho.2024.05.366
pubmed: 38788924
Lambrecht M, Melidis C, Sonke JJ, Adebahr S, Boellaard R, Verheij M, Guckenberger M, Nestle U, Hurkmans C (2016) Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective. Radiat Oncol 11:7. https://doi.org/10.1186/s13014-015-0567-5
doi: 10.1186/s13014-015-0567-5
pubmed: 26791788
pmcid: 4721147
Giuliani M, Mathew AS, Bahig H, Bratman SV, Filion E, Glick D, Louie AV, Raman S, Swaminath A, Warner A et al (2018) SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer‑A Safety and Efficacy Trial. Clin Lung Cancer 19(4):e529–e532
pubmed: 29759332
doi: 10.1016/j.cllc.2018.04.001
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A et al (2021) Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol 7(10):1476–1485
pubmed: 34455431
pmcid: 8404145
doi: 10.1001/jamaoncol.2021.2939
Lubgan D, Semrau S, Lambrecht U, Gaipl US, Fietkau R (2022) 12 x 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma? Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 198(2):110–122
pubmed: 34255094
doi: 10.1007/s00066-021-01811-3
Das A, Giuliani M, Bezjak A (2023) Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy. Semin Radiat Oncol 33(2):172–180
pubmed: 36990634
doi: 10.1016/j.semradonc.2022.11.007
Brunner TB, Blanck O, Lewitzki V, Abbasi-Senger N, Momm F, Riesterer O, Duma MN, Wachter S, Baus W, Gerum S et al (2019) Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 132:42–47
pubmed: 30825968
doi: 10.1016/j.radonc.2018.11.015
Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM et al (2016) Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 95(5):1399–1404
pubmed: 27319288
pmcid: 7771381
doi: 10.1016/j.ijrobp.2016.03.050
Sheikh S, Chen H, Sahgal A, Poon I, Erler D, Badellino S, Dagan R, Foote MC, Louie AV, Redmond KJ et al (2022) An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. Radiother Oncol 167:187–194
pubmed: 34952002
doi: 10.1016/j.radonc.2021.12.018
Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S94–100
Bae SH, Chun SJ, Chung JH, Kim E, Kang JK, Jang WI, Moon JE, Roquette I, Mirabel X, Kimura T et al (2024) Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines. Int J Radiat Oncol Biol Phys 118(2):337–351
pubmed: 37597757
doi: 10.1016/j.ijrobp.2023.08.015
Murray LJ, Sykes J, Brierley J, Kim JJ, Wong RKS, Ringash J, Craig T, Velec M, Lindsay P, Knox JJ et al (2018) Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys 101(4):900–909
pubmed: 29976502
doi: 10.1016/j.ijrobp.2018.04.011
Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U et al (2018) The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 194(5):403–413
Craig T, Xiao Y, McNulty S, Dawson LA (2023) Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial. Pract Radiat Oncol 13(3):239–245
pubmed: 36581199
doi: 10.1016/j.prro.2022.11.013
Dawson LA, Winter K, Knox J, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig T et al (2022) NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiat Oncol Biol Phys 114(5):1057
doi: 10.1016/j.ijrobp.2022.09.002
Brunner TB, Haustermans K, Huguet F, Morganti AG, Mukherjee S, Belka C, Krempien R, Hawkins MA, Valentini V, Roeder F (2021) ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Radiother Oncol 154:60–69
pubmed: 32861703
doi: 10.1016/j.radonc.2020.07.052
Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J et al (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72(3):678–686
pubmed: 18395362
doi: 10.1016/j.ijrobp.2008.01.051
Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS et al (2015) Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121(7):1128–1137
pubmed: 25538019
doi: 10.1002/cncr.29161
Bernard V, Herman JM (2020) Pancreas SBRT: Who, What, When, Where, and How. Pract Radiat Oncol 10(3):183–185
pubmed: 31760165
doi: 10.1016/j.prro.2019.11.005
Palta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N et al (2019) Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol 9(5):322–332
pubmed: 31474330
doi: 10.1016/j.prro.2019.06.016
Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL et al (2017) Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer: A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 193(6):433–443
Michalet M, Bordeau K, Cantaloube M, Valdenaire S, Debuire P, Simeon S, Portales F, Draghici R, Ychou M, Assenat E et al (2022) Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study. Front Oncol 12:842402
pubmed: 35356227
pmcid: 8959839
doi: 10.3389/fonc.2022.842402
Rühle A, Andratschke N, Siva S, Guckenberger M (2019) Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 18:104–112
pubmed: 31341985
pmcid: 6630187
Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A et al (2019) The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus 5(6):958–969
pubmed: 31248849
doi: 10.1016/j.euf.2019.06.002
Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W et al (2018) Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer 124(5):934–942
pubmed: 29266183
doi: 10.1002/cncr.31156
National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer Version 1.2024—June 21, 2023
(2023) Leitlinienprogramm Onkologie: S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 4.0, Februar 2023
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste B, Davey R, Ruben J, Foroudi F, Higgs BG, Lin C et al (2023) TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). Int J Radiat Oncol Biol Phys 117(2):3
doi: 10.1016/j.ijrobp.2023.06.208
Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, Hardcastle N, Montgomery R, Vanneste B, Khoo V et al (2018) TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney—FASTRACK II. BMC Cancer 18(1):1030
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B et al (2024) Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol 25(3):308–316
pubmed: 38423047
doi: 10.1016/S1470-2045(24)00020-2
Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A, Staehler M, Onishi H, Wersall P, Nomiya T (2016) Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol 12(5):637–645
pubmed: 26837701
doi: 10.2217/fon.16.2
Kirste S, Rühle A, Zschiedrich S, Schultze-Seemann W, Jilg CA, Neumann-Haefelin E, Lo SS, Grosu AL, Kim E (2022) Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease-Results of a Prospective Trial. Cancers (basel) 14(20)
Herndon J, Hallemeier C, Jethwa K, Shariff A, Bancos I (2023) Radiation of bilateral adrenal metastases is associated with a high risk of primary adrenal insufficiency. Clin Endocrinol (oxf) 99(1):35–42
pubmed: 36905107
doi: 10.1111/cen.14911
Buergy D, Wurschmidt F, Gkika E, Horner-Rieber J, Knippen S, Gerum S, Balermpas P, Henkenberens C, Voglhuber T, Kornhuber C et al (2021) Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. Int J Cancer 149(2):358–370
pubmed: 33682927
doi: 10.1002/ijc.33546